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ABSTRACT
OBJECTIVE
To assess short term mortality risks and excess 
mortality associated with exposure to ozone in several 
cities worldwide.
DESIGN
Two stage time series analysis.
SETTING
406 cities in 20 countries, with overlapping periods 
between 1985 and 2015, collected from the database of 
Multi-City Multi-Country Collaborative Research Network.
POPULATION
Deaths for all causes or for external causes only 
registered in each city within the study period.
MAIN OUTCOME MEASURES
Daily total mortality (all or non-external causes only).
RESULTS
A total of 45 165 171 deaths were analysed in the 
406 cities. On average, a 10 µg/m3 increase in ozone 
during the current and previous day was associated 
with an overall relative risk of mortality of 1.0018 
(95% confidence interval 1.0012 to 1.0024). Some 
heterogeneity was found across countries, with 
estimates ranging from greater than 1.0020 in the 
United Kingdom, South Africa, Estonia, and Canada 
to less than 1.0008 in Mexico and Spain. Short term 
excess mortality in association with exposure to ozone 
higher than maximum background levels (70 µg/
m3) was 0.26% (95% confidence interval 0.24% to 
0.28%), corresponding to 8203 annual excess deaths 
(95% confidence interval 3525 to 12 840) across the 
406 cities studied. The excess remained at 0.20% 
(0.18% to 0.22%) when restricting to days above the 
WHO guideline (100 µg/m3), corresponding to 6262 
annual excess deaths (1413 to 11 065). Above more 
lenient thresholds for air quality standards in Europe, 
America, and China, excess mortality was 0.14%, 
0.09%, and 0.05%, respectively.
CONCLUSIONS
Results suggest that ozone related mortality could 
be potentially reduced under stricter air quality 
standards. These findings have relevance for the 
implementation of efficient clean air interventions and 
mitigation strategies designed within national and 
international climate policies.
Introduction
Ground level ozone is a highly reactive, oxidative gas 
commonly found in urban and suburban environ­
ments, mostly derived from anthropogenic emissions. 
Numerous epidemiological studies and several reviews 
from health and environmental agencies worldwide 
have reported that exposure to this pollutant is 
associated with adverse health outcomes, including 
increased short term mortality and morbidity.1­4 
Evidence on the health impacts related to ozone 
exposure has important implications in climate change 
research, as ozone levels are predicted to increase with 
global warming.5
Short term ozone­mortality associations have been 
widely assessed in several multi­location time series 
studies in Europe, the United States, Canada, Latin 
America, and Asia.2 6­8 The general methodological 
framework consists of pooling location specific 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Studies on the short term association between ground level ozone and mortality 
have been mostly performed in a few locations, in limited geographical areas, 
and using various designs and modelling approaches
Although most of the studies found positive associations, results are 
heterogeneous, and a critical comparison across different countries and regions 
is made difficult by the limited statistical power and differences across studies
Estimates of the association are usually reported as relative risks, a summary 
measure that does not quantify the actual health impact and makes it difficult to 
evaluate comparative health benefits of different regulatory limits
WHAT THIS STUDY ADDS
This large multi-country study found increased mortality risks associated with 
exposure to ozone across locations and countries, with an average 0.18% per 10 
µg/m3, reinforcing the evidence of a potential causal association
Risk estimates were translated in measures of excess mortality, and it was found 
that more than 6000 deaths each year, corresponding to 0.20% of the total 
mortality, would have been avoided in the 406 cities studied if countries had 
implemented stricter air quality standards compliant with the WHO guideline
Moreover, smaller but still substantial mortality impacts were found below WHO 
guideline, supporting the WHO initiative of encouraging countries to revisit 
current air quality guidelines and enforcing stronger emission restrictions to 
meet these recommendations
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estimated risks, accounting for potential heterogeneity 
in the magnitude of the effect and uncertainty. In 
addition, the increased statistical power of multi­
location analyses allows for the exploration of 
potentially complex features of the association (ie, 
non­linearity, delayed effects and harvesting, or 
differential risks by season).9­11 However, previous 
multi­location studies included a small number 
of cities and countries, were generally of limited 
geographical scope, and applied heterogeneous ana­
lytical approaches and modelling choices, making 
it difficult to draw consistent and comprehensive 
conclusions across different regions of the world.
Although ozone­mortality associations have been 
widely assessed, results are rarely reported in terms 
of health impacts, such as excess deaths.12 Available 
figures are mostly derived from long term exposure 
metrics and risks estimated in specific subgroups, 
which are usually extrapolated to the general popu­
lation.13 14 Quantification of health burdens from 
air pollution can be extremely useful for the design 
of efficient public health interventions, including 
the definition, assessment, and review of air quality 
standards. Current air quality standards vary greatly 
between countries, and only a few of them meet the 
stricter World Health Organization recommendation.15 
Comparting the effects on health of ozone levels above 
different air quality standards can provide valuable 
insights into potential public health benefits achieved 
by strengthening current clean air policies. Although 
a few studies have attempted to tackle this problem, 
a widespread evaluation across several countries, 
which would help to identify more affected areas with 
a greater need for intervention, is still lacking.16 17
We carried out a multi­location time series analysis 
of mortality associated with short term exposure to 
ozone using data from 406 cities in 20 countries from 
multiple geographical regions. Next, we explored 
potential complexities of the association—namely, 
non­linearity, mortality displacement, and seasonality. 
Finally, we quantified the impacts on ozone associated 
mortality of specific concentration ranges consistent 
with the current air quality standards levels and then 
compared these estimates across countries.
Methods
Data collection
We initially extracted data for 434 locations across the 
20 countries from the database of the Multi­city Multi­
country (MCC) Collaborative Research Network (http://
mccstudy.lshtm.ac.uk/) available at the time of the 
study. These include location specific daily mortality 
counts and environmental measures (weather and 
air pollutants) in largely overlapping periods from 1 
January 1985 to 31 December 2015. For each location 
we derived daily time series of ozone (maximum eight 
hour average), particulate matter with an aerodynamic 
diameter less than or equal to 10 µm (PM10, per µg/m
3, 
24 hour average), particulate matter with an aero­
dynamic diameter less than or equal to 2.5 µm (PM2.5, 
per µg/m3, 24 hour average), nitrogen dioxide (24 
hour average), total mortality, mean temperature (°C), 
and relative humidity (%). Mortality was represented 
by all cause deaths in Canada, the Czech Republic, 
Estonia, France, Germany, Greece, Italy, Japan, 
Mexico, Portugal, South Africa, South Korea, Sweden, 
Taiwan, UK, and US, whereas deaths due to non­
external causes (eg, excluding self­intentional harm, 
poisoning) were used in Australia, China, and Spain, 
and non­external causes other than unintentional 
injuries in Switzerland (see supplementary eMethods 1 
for the specific international classification of diseases 
codes used in each country). City specific air pollution 
series were derived from daily measurements of one 
or more monitors of the national or regional network. 
When more than one monitor was available, we 
computed the daily level of each pollutant (24 hour 
average or eight hour maximum) as the average across 
monitors of the city, consistent with previous multi­
city studies.2 We excluded 28 cities as a result of poor 
quality data or limited periods (less than three years), 
with 406 locations included in the final analysis (see 
supplementary eMethods 1 for a detailed description of 
the data, exposure assessment, and exclusion criteria).
Statistical analysis
The general statistical framework applied here is 
an extension of the classic two stage design6 and 
incorporates complex multivariable associations, 
hierarchical pooling methods, and the computation 
of impact measures.18­20 Briefly, we first estimated 
city specific ozone­mortality risks from separate 
time series regression models and then pooled these 
through a meta­analysis in the second stage. In a final 
step, we derived impact estimates, expressed as excess 
mortality fractions associated with ozone, from the 
pooled country specific risks and city specific exposure 
series. Using this general statistical framework, we 
performed a set of additional and sensitivity analyses 
to investigate specific features of the association. The 
analyses were conducted with R software (version 
3.5.2) using the dlnm and mixmeta packages.
Main analysis
In the first stage, we performed city specific time series 
analyses using generalised linear models with quasi­
Poisson family. In this type of regression model, to 
properly scale the standard deviation of the coefficients 
proportionally to the potential overdispersion, a quasi­
likelihood is applied. This phenomenon is common 
in these types of data, when the variability is larger 
than that expected under the assumption of a Poisson 
distribution. We assessed short term ozone­mortality 
associations using unconstrained distributed lag linear 
models.11 21 These models account for delayed effects 
of time varying exposures and quantify net effects 
over a predefined lag period.20 For the main model, we 
selected lag 0­1, estimating cumulative associations 
with the same and previous day’s exposures. The 
regression model included a natural spline of time with 
seven degrees of freedom each year, selected based on 
a quasi­likelihood version of the Akaike information 
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criterion for 4, 6, 7, 8, and 10 degrees of freedom, and 
indicator variables for the day of the week, to control 
for long term, seasonal, and weekly variations in risk. 
Unlike in most previous studies on ozone, we applied 
a stricter control for temperature by using distributed 
lag non­linear models, an extension of distributed 
lag linear models for modelling complex non­linear 
and lagged associations. Following modelling choices 
applied in published analyses, we modelled the net 
temperature­mortality association over lag 0­21 (see 
supplementary eMethods 2).22
In the second stage we pooled city specific estimates 
through a multilevel meta­analysis. This novel meta­
analytical model defines more complex random effects 
that can account for variations in risk across two 
nested grouping levels, represented by cities within 
countries.19 This approach allowed the derivation of 
improved estimates of ozone­mortality associations 
at both city and country level, defined as best linear 
unbiased predictions. Best linear unbiased predictions 
borrow information across units within the same 
hierarchical level and can provide more accurate 
estimates, especially in locations with small daily 
mortality counts or short series. We tested the presence 
of heterogeneity and reported it using multilevel 
extensions of Cochran Q test and I2 statistic.23 Asso­
ciation estimates, expressed as relative risk of 
mortality per 10 µg/m3 increase of ozone and 95% 
confidence interval were derived for each country from 
the corresponding best linear unbiased predictions.
Risk estimates for ozone related mortality were then 
translated into impact measures, represented by excess 
mortality, following a method described elsewhere.18 
Briefly, for each city we computed the daily number of 
deaths attributable to ozone (or daily excess deaths) 
using the corresponding risk estimate associated 
with the level of ozone in each day. Regarding the 
latter, we used country specific best linear unbiased 
predictions instead of the city specific estimates 
to avoid imbalances due to selection of cities and 
periods within each country. City specific estimates 
were reported as annual average number of excess 
deaths and 95% confidence intervals, so allowing for 
a proper comparison between locations with different 
lengths of study period. Then, country specific impacts 
were represented by excess mortality fractions (%) 
computed as the sum of the city specific daily excess 
deaths divided by the total mortality for each country. 
We used fractions instead of number of excess deaths, 
as excess deaths are not comparable across countries 
given the dependency on the denominator (ie, total 
mortality), which at the same time depends on the 
number of locations included. Although no evidence 
of a “safe” threshold exists, we computed associated 
deaths only for days with ozone levels above 70 µg/m3, 
as in previous health impact assessments.4 We 
considered this counterfactual scenario of 70 µg/m3 
because ozone levels below this threshold could be 
mostly attributed to non­anthropogenic sources. A 
counterfactual scenario defined at 0 µg/m3 would not 
be appropriate either as it is not realistic given the 
ubiquitous presence of low levels of ozone derived 
from natural sources. We also disaggregated mortality 
impacts into contributions for exposure ranges above 
and between current air quality standards: 100 µg/m3 
(WHO), 120 µg/m3 (European Union directive), 
140 µg/m3 (National Ambient Air Quality Standard 
(NAAQS) in the US, about 0.070 parts per million), 
and 160 µg/m3 (Chinese Ambient Air Quality Standard 
(CAAQS) level 2).15
Additional complexities and sensitivity analyses
We performed a series of additional subanalyses to 
explore more complex features of the association, such 
as potential non­linearity, lagged effects, and seasonal 
differences. Firstly, we modelled exposure­response 
functions with a non­linear function consisting of a 
cubic B spline with internal knots at 50 µg/m3 and 
60 µg/m3 of ozone. Secondly, we assessed delayed risks 
and potential mortality displacement by extending the 
lag dimension of the distributed lag linear model up 
to 30 days. Lag­response associations were modelled 
using a natural cubic spline with three internal knots 
placed at equally spaced lag values in the log scale. 
Thirdly, we assessed seasonal differences through 
interaction models between an indicator of season and 
the distributed lag linear model of ozone, as described 
elsewhere.24 We derived the ozone­mortality risk 
for the warm season (June to August in the northern 
hemisphere, December, January, and February in the 
southern hemisphere) and cold seasons (the remaining 
months).
Modelling choices in the main model and extensions 
previously described were assessed and compared 
through the quasi­likelihood version of the Akaike 
information criterion and multivariate extensions of 
the Wald test. For sensitivity analyses, we first assessed 
changes in control for time trends and the potential 
confounding from other air pollutants (PM10, PM2.5, and 
nitrogen dioxide) and relative humidity by including 
each of these terms separately in the model. We then 
assessed the exclusion of a subset of US cities with 
data for summer only, which were included in the main 
analysis, and then different modelling approaches to 
control for temperature. See supplementary eMethods 
1 and 2 for a description of the modelling details.
Patient and public involvement
This was a multinational collaboration using aggre­
gated city level mortality and environmental data. 
Patients and members of the public did not contribute 
to the steering committee, design, or other areas of the 
study, which involved complex research methods and 
analysis.
Results
Table 1 provides a summary description of the data 
included for each country. A total of 45 165 171 deaths 
were analysed in the 406 cities, with an average time 
series of 13 years. Average annual mean ozone levels 
were widely heterogeneous across cities both between 
and within countries (fig 1). For example, lower levels 
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were registered in Australian and northern European 
cities, whereas higher annual averages were found in 
some cities in the central area of the US, in Mexico, 
and in Taiwan. Supplementary eTable1 provides 
country specific descriptive summaries of the other 
air pollutants and humidity and eTable 2 reports the 
corresponding city specific descriptive results.
On average, each 10 µg/m3 increase in ozone was 
associated with an overall relative risk of mortality of 
1.0018 (95% confidence interval 1.0012 to 1.0024) 
(fig 2). Some heterogeneity was found across country 
and city specific risks (I2=29.8%, Cochran Q P<0.001). 
Larger risk estimates were found in the UK (1.0035 
(1.0024 to 1.0046)), South Africa (1.0027 (1.0013 
to 1.0042)), Estonia (1.0023 (1.0006 to 1.0040)), 
and Canada (1.0023 (1.0013 to 1.0032)), whereas 
Australia, China, the Czech Republic, France, Germany, 
Italy, Japan, South Korea, Sweden, Switzerland, and 
the US showed similar risks, ranging between 1.0014 
and 1.0020. Lower and imprecise associations were 
estimated for Greece (1.0011 (0.9995 to 1.0028)), 
Mexico (1.0008 (1.000 to 1.0015)), Portugal (1.0011 
(0.9997 to 1.0026)), Spain (1.0006 (0.9992 to 
1.0019)), and Taiwan (1.0010 (0.9999 to 1.0021)). 
Supplementary eFigure 1 provides the corresponding 
figures with the relative risks for an increase in 10 parts 
per billion of ozone.
Figure 3 depicts the excess mortality fractions 
above the WHO guideline and their distribution across 
intervals between the other air quality standards for 
each country, whereas supplementary eTable 3 and 
eTable 4 report the corresponding figures for excess 
fractions for total ozone (>70 µg/m3) and above and 
between air quality standards. Table 2 shows fractions 
and annual number of excess deaths associated with 
ozone for the total range of exposure and above the 
WHO guideline for a selection of the main cities in 
each country and overall across the 406 locations 
(supplementary eTable5 shows the estimates for all 
cities). Total mortality associated with ozone greater 
than 70 µg/m3 accounted for 0.26% of deaths (95% 
confidence interval 0.24% to 0.28%), which translates 
into 8203 annual excess deaths (95% confidence 
interval 3525 to 12 840) across the 406 locations 
studied (table 2). A substantial residual excess mortality 
of 0.20% (95% confidence interval 0.18% to 0.22%) 
corresponding to 6262 (95% confidence interval 
1413 to 11 065) annual excess deaths remained when 
restricting to days with levels above the WHO guideline 
of 100 µg/m3. This proportion varied greatly by 
country, with considerably larger fractions in Mexico 
(0.52% (0.14% to 0.92%)) and Taiwan (0.37% (0.08% 
to 0.64%)) (fig 3, supplementary eTable 3). A mortality 
excess around 0.20% was estimated in Canada, China, 
Italy, Japan, South Africa, Switzerland, and the US, 
whereas France, Germany, South Korea, and the 
UK reported smaller percentages, ranging between 
0.14% and 0.05% (fig 3, supplementary eTable 3). 
Imprecise or almost null estimates were found in the 
Czech Republic, Estonia, Greece, Portugal, Spain, and 
Sweden (supplementary eTable 3). Overall mortality 
fractions above more lenient air quality standards 
(ie, the European Union, NAAQS, and CAAQS) 
decreased progressively to 0.14%, 0.09%, and 0.05%, 
respectively (supplementary eTable 3). Only Mexico 
reported a considerably higher fraction, of 0.35% 
above the highest air quality standards of 160 µg/m3, 
although this finding was highly uncertain (black bar 
in fig 3, supplementary eTable 3). Null excess deaths 
were found in Australia, as daily exposure levels were 
all below 70 µg/m3. A similar pattern was found across 
estimates for the main cities in each country (table 
Table 1 | Environmental and mortality data
Countries
No of 
cities Period No of deaths*
Median (interquartile range) 
No of daily deaths
Median (interquartile range) 
ozone level (µg/m3)†
Median (interquartile range) 
mean temperature (°C)
Australia 3 2000-19 513 527 49.3 (43.7-55.7) 31.2 (24.2-38.6) 18.3 (14.8-21.5)
Canada 26 1986-2011 2 914 630 12.8 (10.5-15.3) 69.2 (53.9-88.4) 7.3 (−1.0-15.7)
China 3 1996-2015 780 655 87.3 (71.7-140.3) 49.3 (27.8-77.5) 20.4 (13.0-25.7)
Czech Republic 1 1994-2009 214 062 36.0 (32.0-41.0) 69.3 (47.4-95.0) 9.2 (2.5-15.3)
Estonia 4 2002-15 80 043 5.0 (3.5-6.5) 48.9 (36.7-61.8) 6.0 (0.2-13.6)
France 18 2000-10 1 197 555 16.3 (13.7-19.1) 67.8 (46.8-87.4) 12.7 (7.6-17.9)
Germany 12 1993-2015 3 099 176 30.4 (26.4-34.8) 57.1 (35.8-79.2) 10.5 (4.8-15.9)
Greece 1 2001-10 287 969 78.0 (70.0-87.0) 75.1 (52.8-97.5) 17.9 (12.9-24.9)
Italy 9 2006-15 373 421 15.1 (12.6-17.9) 74.1 (50.5-97.0) 15.8 (10.2-22.1)
Japan 45 2011-15 1 856 232 22.3 (19.1-25.7) 78.5 (62.4-98.4) 16.1 (7.5-22.7)
Mexico 7 2000-12 2 018 313 61.0 (53.7-69.4) 108.9 (85.1-135) 18.6 (15.9-20.5)
Portugal 2 1997-2012 536 958 47.0 (41.0-54.0) 64.2 (50.2-79.2) 16.1 (12.5-19.6)
South Africa 5 2004-13 924 478 58.4 (48.8-67.0) 69.5 (52.9-89.5) 18.3 (14.2-21.2)
South Korea 7 1999-2015 1 662 199 38.3 (34.0-42.7) 59.5 (42.7-81.9) 15.1 (5.8-22.1)
Spain 48 2004-14 1 294 162 6.7 (5.1-8.4) 70.0 (53.9-84.7) 15.3 (10.3-21.1)
Sweden 1 1990-2010 201 197 26.0 (22.0-30.0) 61.9 (48.9-76.0) 6.8 (1.2-13.9)
Switzerland 8 1995-2013 230 587 4.2 (2.9-5.6) 72.8 (47.0-98.1) 10.7 (4.4-16.5)
Taiwan 3 2008-14 443 680 57.0 (51.0-63.7) 109.1 (82.1-138.6) 24.8 (20-28.2)
UK 15 1993-2006 2 073 285 28.4 (24.5-32.9) 51.6 (36.7-65.2) 10.4 (6.5-14.6)
USA 188 1985-2006 24 463 042 16.3 (13.6-19.3) 80.1 (58.9-104.0) 14.9 (7.5-21.9)
*Deaths due to non-external causes (Australia, China, Spain, Switzerland (including unintentional injuries)) or to all cause mortality (remaining countries). See supplementary eMethods 1 for a 
description of the data. Country specific summaries of other air pollutants and relative humidity are provided in supplementary eTable 1 and city specific descriptive summaries are reported in 
supplementary eTable 2.
†Daily maximum eight hour mean.
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2). A substantial number of annual excess deaths 
were associated with ozone levels above the WHO 
guideline—namely, 694 (95% confidence interval 22 
to 1317) in the Valley of Mexico, 211 (112 to 307) 
in Los Angeles, 170 (40 to 304) in Tokyo, 128 (59 to 
197) in Toronto, 82 (19 to 148) in Johannesburg, 48 
(0 to 96) in Paris, and 37 (15 to 57) in London (table 
2). Supplementary eTable 5 shows the corresponding 
estimates for the 406 cities.
Additional analyses suggested no evidence of non­
linearity in the concentration­response association 
(according to the quasi­likelihood version of the Akaike 
information criterion) (supplementary eFigure 2). The 
assessment of the lagged associations confirmed an 
immediate ozone­mortality association during the 
first week. However, lag specific estimates below 1 
were found after the second week, which resulted in a 
slightly lower overall cumulative association of 1.0015 
(95% confidence interval 0.9991 to 1.0032) when 
considering the delayed effects over the first 30 days 
after the exposure. Finally, no evidence of seasonal 
differences in ozone­mortality association were found 
(warm season: 1.0012 (95% confidence interval 1.000 
to 1.0026); cold season: 1.0015% (1.0006 to 1.0024), 
Wald test P=0.37).
Results from sensitivity analyses suggest that risk 
estimates of the main analysis were robust to the 
different modelling choices related to the control 
for time trends and adjustment by the three air 
pollutants and humidity (supplementary eTable 6). 
However, ozone­mortality risk estimates seemed to be 
sensitive to the approach to control for temperature 
(supplementary eFigure 3). We found larger ozone­
mortality association estimates using less stringent 
control, although quasi­likelihood Akaike information 
criterion values suggested that the model with 
distributed lag non­linear model of temperature (main 
model) provided the best fit.
Discussion
On average, this study found an overall short term 
ozone­mortality association of 1.0018 (95% confidence 
interval 1.0012 to 1.0024) per 10 µg/m3 increase 
in ozone. This evidence is supported by previous 
epidemiological and experimental studies suggesting 
several pathophysiological mechanisms (e.g. systemic 
150
Average annual
mean 8 hours
maximum
O
3
 (μg/m3)
120
90
60
30
Fig 1 | Geographical distribution of city specific average annual means of ozone (O3, maximum eight hour average) of 406 cities of the Multi-City 
Multi-Country Collaborative Research Network included in the study
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inflammation, haemostatic altera tions).25 26 Larger 
associations were found in previous multi­country 
studies, including a subset of countries investigated 
here (eg, relative risk of 1.0022 in APHEA (Air Pollution 
and Health: A European Approach), 1.0026 in APHENA 
(Air Pollution and Health: A Combined European and 
North American Approach), per 10 µg/m3 increase),11 
21 or single country studies (eg, relative risk of 1.0025 
in the US (originally 1.0052 per 10 parts per billion 
increase), and China 0.55% per 10 µg/m3 increase, and 
1.015 in Italy).27­29 Differences in the definition of the 
exposure variable (eg, moving average, single lag) and 
modelling approach could explain these discrepancies 
in the magnitude of the association. For example, 
compared with previous studies, we applied a stronger 
control for temperature (ie, distributed lag non­linear 
models), fully accounting for non­linearity and lagged 
temperature­mortality associations.22 In fact, results 
from sensitivity analyses are consistent with previous 
findings showing that ozone­mortality risk estimates 
were sensitive to the modelling strategy to control for 
temperature, reporting larger risks when using simpler 
approaches (supplementary eFigure 3).27 Moreover, 
one of the novelties of the applied statistical framework 
is the use of multilevel meta­analytical models in the 
second stage, properly accounting for heterogeneity 
across cities and countries.
Our results showed important differences in the 
ozone­mortality association across countries. For 
example, while some areas such as UK, South Africa, 
Canada, and Estonia reported the largest risk estimates 
above 1.0020, smaller or imprecise estimates below 
1.0011 were found in Greece, Mexico, Spain, and 
Taiwan. This unclear pattern would suggest that 
although several community level factors have been 
proposed as potential modifiers in single country 
studies (eg, population characteristics), these might 
not fully characterise differences between countries.30 
Future multi­country studies are needed to provide 
further evidence on the factors defining the level of 
vulnerability of a population to air pollution.
This study also provides evidence on the potential 
public health benefits of stricter clean air policies. 
In particular, we found that 0.20% excess mortality, 
which translates into more than 6000 deaths each 
year, related to short term exposure to ozone could have 
been avoided if ambient levels were below the WHO 
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guideline of 100 µg/m3 in the 406 cities included in the 
study. Recent reviews found that most of the current 
air quality standards do not comply with the WHO 
air quality guideline,15 and that 80% of the world’s 
population in urban areas are exposed to air pollution 
levels above this threshold.31 Moreover, an additional 
0.06% of excess deaths is associated with ozone levels 
between 70 µg/m3 and 100 µg/m3. These findings 
support the WHO initiative of encouraging countries 
to reconsider current air quality standards and enforce 
stronger emission restrictions and other public 
health interventions to meet its recommendations. 
Additionally, our results have important implications 
for healthcare practice. Apart from the implementation 
of clean air policies, individual strategies to reduce 
personal exposure to air pollutants are also desi­
rable.32 In this regard, clinicians play an important 
role in counselling patients with potentially a higher 
susceptibility to adverse health outcomes related to 
air pollution. For example, professionals can advise 
sensitive individuals to stay indoors or avoid doing 
exercise during episodes of high ambient ozone.
Previous studies showed that important health 
benefits could be achieved if reductions of ozone levels 
are reached.9 13 16 However, in this multi­country study 
we compared excess mortality estimates across air 
quality standards and countries, providing additional 
insights on specific areas with more urgent need of 
further interventions. For example, we found that 
0.52% of total mortality in Mexico was associated 
with ozone above the WHO limit, the largest mortality 
fraction among the studied countries. This was 
associated with the highest ozone levels registered in 
the Mexican cities, especially above the 160 µg/m3 
limit, which is close to its current air quality standards 
of 156 µg/m3. This means that attaining the current 
lenient standards would prevent a substantial 
proportion of ozone related deaths in this country. In 
contrast, results for the UK show a lower mortality 
fraction, despite the strongest ozone­mortality 
association, owing to the lower ozone levels registered 
in this country.
Strengths and limitations of this study
This large epidemiological investigation on short 
term ozone­mortality associations included almost 
50 million deaths from 406 cities in 20 countries from 
different regions across the world. Given its large sample 
size and wide geographical coverage, we were able to 
obtain consistent evidence of an association between 
short term exposure to ozone and total mortality. In 
addition, we provided ozone related impact estimates, 
quantified as excess mortality, across different air 
quality standards, countries and cities, providing 
evidence with important public health implications.
We were able to explore additional complexities of the 
association by taking advantage of the large statistical 
power and advanced statistical techniques. Firstly, our 
results support the conclusions of previous studies on 
a generally linear concentration­response functions, 
with no indication of threshold.9 27 Secondly, we found 
evidence of a potential mortality displacement in the 
third and fourth week after the exposure. A similar lag 
pattern has been previously observed.10 11 However, 
potential mechanisms explaining this delayed and 
sustained pattern remain unclear. Finally, we found no 
evidence of seasonal differences in the ozone­mortality 
association. Previous multi­site studies have provided 
Table 2 | Excess mortality associated with ozone for total (>70 µg/m3) and above World Health Organization guideline of 100 µg/m3 in main cities of 
each participating country and overall estimates for the 406 cities
Countries Cities
Total (>70 µg/m3)* Above WHO guideline (100 µg/m3)
% Excess fraction  
(95% CI)
No of annual excess  
deaths (95% CI)
% Excess fraction  
(95% CI)
No of annual excess 
deaths (95% CI)
Australia† Sydney 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0)
Canada Toronto 0.59 (0.34 to 0.85) 159 (90 to 228) 0.48 (0.22 to 0.73) 128 (59 to 197)
China Shanghai 0.32 (0.04 to 0.57) 117 (15 to 209) 0.27 (−0.01 to 0.53) 99 (−4 to 195)
Czech Republic Prague 0.27 (0.02 to 0.48) 38 (3 to 69) 0.20 (−0.06 to 0.44) 29 (−9 to 63)
Estonia Tallinn 0.01 (0.00 to 0.02) 1 (0 to 1) 0.00 (−0.01 to 0.01) 0 (−1 to 1)
France Paris 0.15 (0.05 to 0.26) 70 (24 to 119) 0.11 (0.00 to 0.21) 48 (0 to 96)
Germany Berlin 0.12 (0.04 to 0.20) 46 (14 to 74) 0.08 (−0.01 to 0.17) 30 (−3 to 62)
Greece Athens 0.16 (−0.07 to 0.41) 52 (−23 to 132) 0.11 (−0.13 to 0.37) 35 (−42 to 117)
Italy Rome 0.27 (0.05 to 0.52) 69 (13 to 132) 0.19 (−0.05 to 0.44) 48 (−12 to 111)
Japan Tokyo 0.27 (0.14 to 0.40) 249 (127 to 371) 0.18 (0.04 to 0.32) 170 (40 to 304)
Mexico Valley of Mexico 0.73 (0.04 to 1.38) 707 (39 to 1,339) 0.72 (0.02 to 1.36) 694 (22 to 1,317)
Portugal Lisbon 0.09 (−0.03 to 0.2) 20 (−6 to 45) 0.04 (−0.09 to 0.17) 9 (−20 to 39)
South Africa City of Johannesburg 0.32 (0.15 to 0.49) 121 (59 to 187) 0.22 (0.05 to 0.39) 82 (19 to 148)
South Korea Seoul 0.10 (0.03 to 0.17) 41 (13 to 71) 0.06 (−0.01 to 0.14) 27 (−3 to 58)
Spain Madrid 0.03 (−0.04 to 0.11) 9 (−12 to 31) 0.01 (−0.07 to 0.10) 3 (−21 to 27)
Sweden Stockholm 0.10 (0.02 to 0.18) 10 (2 to 18) 0.03 (−0.07 to 0.13) 3 (−7 to 13)
Switzerland Zurich 0.31 (0.05 to 0.54) 13 (2 to 22) 0.23 (−0.02 to 0.48) 10 (−1 to 20)
Taiwan Taipei 0.34 (−0.05 to 0.72) 131 (−21 to 276) 0.28 (−0.11 to 0.67) 109 (−43 to 258)
UK London 0.10 (0.07 to 0.12) 63 (44 to 81) 0.06 (0.02 to 0.09) 37 (15 to 57)
USA Los Angeles 0.41 (0.24 to 0.57) 242 (142 to 335) 0.36 (0.19 to 0.52) 211 (112 to 307)
20 MCC countries‡ 406 MCC cities 0.26 (0.24 to 0.28) 8,203 (3,525 to 12 840) 0.20 (0.18 to 0.22) 6,262 (1,413 to 11 065)
*Total refers to ozone related deaths when levels above 70 µg/m3 (defined as maximum background levels).
†No excess mortality associated with ozone were found in Australia, as daily ozone levels were below the maximum background level set up at 70 µg/m3.
‡Countries contributing to the Multi-City Multi-Country (MCC) Collaborative Research Network included in the present study.
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conflicting results, with larger risks in cold seasons in 
Asia27 and in warm seasons in the US and Europe.6 
Further analyses are warranted to characterise different 
patterns across regions.
This study has some limitations. Firstly, our 
results should not be considered truly global 
estimates, because several areas of the world 
such as South America, Africa, and the Middle 
East are unrepresented or were not assessed. In 
addition, the reported nationwide results might 
not be representative of the true impacts for some 
countries with a limited number of cities included 
in the study (eg, Sweden, Czech Republic, China). 
In particular, the estimated number of total excess 
deaths attributed to ozone should be interpreted as 
the sum of impacts in the 406 observed locations 
and not as total estimates across the 20 countries. 
Although excess fractions could be considered proper 
representations of the impacts for each country, the 
total excess number of deaths for each country is 
highly dependent on the total mortality considered in 
the study—that is, the number of locations included 
in each country. Systematic differences could also 
exist between countries in the characteristics of 
monitors (type, proximity to study area), study area 
boundaries, temporal coverage, data processing 
before data collection, and the collection of mortality 
data (eg, case ascertainment, codification). However, 
we ensured that the data fulfilled a minimum set of 
requirements for quality, a similar definition for the 
eight hour maximum metric, and location of the 
monitor (ie, within the study area or close enough 
to ensure its representativeness). Risks and impact 
estimates were only reported for total mortality (ie, 
deaths due to all or non­external causes) and we did 
not seek to identify the sources of heterogeneity of 
the results across countries. We acknowledge that the 
applied approach prevents us from understanding the 
potential mechanisms or differential susceptibility of 
the population, together with contextual differences 
across locations. Further studies are warranted to 
clarify this complex research question, including, for 
example, cause specific mortality and morbidity, and 
more complex two stage analyses. Finally, although 
the risk estimates were small they apply to the 
whole population, thus translating into substantial 
mortality impacts as shown in our estimates of excess 
mortality. By the same token, owing to the nature of 
the study design (time series analysis) the obtained 
excess mortality estimates refer to transient impact 
measures and not to the mortality burden or person 
years of life lost attributed to chronic exposure to 
ozone.33
Conclusions
This large multi­country study provided evidence 
on the short term association between ozone and 
mortality. We also show that clean air policies with 
the enactment of air quality standards can constitute 
essential public health tools to minimise the health 
burden. In particular, our results suggest that ozone 
related health impacts can be largely preventable by 
attaining effective air quality standards in line with 
the WHO guideline. Moreover, interventions to further 
reduce ozone pollution would provide additional 
health benefits, even in regions that meet current 
regulatory standards and guidelines. These findings 
have important implications for the design of future 
public health actions; particularly, for example, in 
relation to the implementation of mitigation strategies 
to reduce the impacts of climate change.
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